Multiplex assay (Mikrogen recomBead) for detection of serum IgG and IgM antibodies to 13 recombinant antigens of Borrelia burgdorferi sensu lato in patients with neuroborreliosis: the more the better?

References

1. Aguero-Rosenfeld M. E. 2008; Lyme disease: laboratory issues. Infect Dis Clin North Am 22:301–313 [View Article][PubMed]
   [Google Scholar]
2. Aguero-Rosenfeld M. E., Wang G., Schwartz I., Wormser G. P. 2005; Diagnosis of Lyme borreliosis. Clin Microbiol Rev 18:484–509 [View Article][PubMed]
   [Google Scholar]
3. CDC 1995; Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease. MMWR Morb Mortal Wkly Rep 44:590–591[PubMed]
   [Google Scholar]
4. Dessau R. B. 2013; Diagnostic accuracy and comparison of two assays for Borrelia-specific IgG and IgM antibodies: proposals for statistical evaluation methods, cut-off values and standardization. J Med Microbiol 62:1835–1844 [View Article][PubMed]
   [Google Scholar]
5. Dessau R. B., Bangsborg J. M., Ejlertsen T., Skarphedinsson S., Schønheyder H. C. 2010a; Utilization of serology for the diagnosis of suspected Lyme borreliosis in Denmark: survey of patients seen in general practice. BMC Infect Dis 10:317 [View Article][PubMed]
   [Google Scholar]
6. Dessau R. B., Ejlertsen T., Hilden J. 2010b; Simultaneous use of serum IgG and IgM for risk scoring of suspected early Lyme borreliosis: graphical and bivariate analyses. APMIS 118:313–323 [View Article][PubMed]
   [Google Scholar]
7. Dessau R. B., Eliasson I., Skarpaas T., Nyman D. 2011; Report from a survey of laboratory methods used in Scandinavia. Testing for Lyme borreliosis in the Nordic countries – variations in strategies and rate of seropositivity http://dskm.dk/Serological-20testing-20for-20Lyme.pdf
   [Google Scholar]
8. Hauser U., Lehnert G., Lobentanzer R., Wilske B. 1997; Interpretation criteria for standardized Western blots for three European species of Borrelia burgdorferi sensu lato. J Clin Microbiol 35:1433–1444[PubMed]
   [Google Scholar]
9. Hauser U., Lehnert G., Wilske B. 1999; Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe. J Clin Microbiol 37:2241–2247[PubMed]
   [Google Scholar]
10. Henningsson A. J., Tjernberg I., Malmvall B. E., Forsberg P., Ernerudh J. 2011; Indications of Th1 and Th17 responses in cerebrospinal fluid from patients with Lyme neuroborreliosis: a large retrospective study. J Neuroinflammation 8:36 [View Article][PubMed]
    [Google Scholar]
11. Henningsson A. J., Christiansson M., Tjernberg I., Löfgren S., Matussek A. 2014; Laboratory diagnosis of Lyme neuroborreliosis: a comparison of three CSF anti-Borrelia antibody assays. Eur J Clin Microbiol Infect Dis 33:797–803 [View Article][PubMed]
    [Google Scholar]
12. Hunfeld K. P., Kraiczy P. 2009; When is the best time to order a Western blot and how should it be interpreted?. Curr Probl Dermatol 37:167–177 [View Article][PubMed]
    [Google Scholar]
13. Hunfeld K. P., Stanek G., Straube E., Hagedorn H. J., Schörner C., Mühlschlegel F., Brade V. 2002; Quality of Lyme disease serology. Lessons from the German proficiency testing program 1999–2001. A preliminary report. Wien Klin Wochenschr 114:591–600[PubMed]
    [Google Scholar]
14. Müller I., Freitag M. H., Poggensee G., Scharnetzky E., Straube E., Schoerner Ch., Hlobil H., Hagedorn H.-J., Stanek G. et al. 2012; Evaluating frequency, diagnostic quality, and cost of Lyme borreliosis testing in Germany: a retrospective model analysis. Clin Dev Immunol 2012:595427 [View Article][PubMed]
    [Google Scholar]
15. Mygland Å., Ljøstad U., Fingerle V., Rupprecht T., Schmutzhard E., Steiner I. 2010; EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17:8–16 [View Article][PubMed]
    [Google Scholar]
16. Pepe M. S. 2003; Combining multiple test results. In The Statistical Evaluation of Medical Tests for Classification and Prediction pp. 267–276 Oxford: Oxford University Press;
    [Google Scholar]
17. R Core Team 2013 R: a Language and Environment for Statistical Computing Vienna: R Foundation for Statistical Computing;
    [Google Scholar]
18. Robertson J., Guy E., Andrews N., Wilske B., Anda P., Granström M., Hauser U., Moosmann Y., Sambri V. et al. 2000; A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. J Clin Microbiol 38:2097–2102[PubMed]
    [Google Scholar]
19. Stanek G., Reiter M. 2011; The expanding Lyme Borrelia complex – clinical significance of genomic species?. Clin Microbiol Infect 17:487–493 [View Article][PubMed]
    [Google Scholar]
20. Stanek G., Fingerle V., Hunfeld K. P., Jaulhac B., Kaiser R., Krause A., Kristoferitsch W., O’Connell S., Ornstein K. et al. 2011; Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 17:69–79 [View Article][PubMed]
    [Google Scholar]
21. Stanek G., Wormser G. P., Gray J., Strle F. 2012; Lyme borreliosis. Lancet 379:461–473 [View Article][PubMed]
    [Google Scholar]
22. Tjernberg I., Henningsson A. J., Eliasson I., Forsberg P., Ernerudh J. 2011; Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. J Infect 62:149–158 [View Article][PubMed]
    [Google Scholar]
23. Wilske B., Hauser U., Lehnert G., Jauris-Heipke S. 1998; Genospecies and their influence on immunoblot results. Wien Klin Wochenschr 110:882–885[PubMed]
    [Google Scholar]
24. Wilske B., Zöller L., Brade V., Eiffert H., Göbel U. B., Stanek G., Pfister H. W. 2000; MIQ12, Lyme-borreliose. In Qualitätsstandards in der Mikrobiologisch-Infektiologischen Diagnostik pp. 1–59 Edited by Mauch H., Lütticken R. Munich: Urban & Fischer Verlag;
    [Google Scholar]